0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Blood-Based Biomarkers in Alzheimer Disease

Christoph Laske, MD
Arch Neurol. 2011;68(5):685-686. doi:10.1001/archneurol.2011.78.
Text Size: A A A
Published online

Extract

O’Bryant and colleagues describe in their recent article1 the identification of a blood-based biomarker panel for classification of patients with Alzheimer disease (AD). If confirmed, this opens an alternative approach to finding useful biomarkers for the early detection of AD using blood as an alternative sampling tissue. A simple blood test could revolutionize AD diagnostics, as it would be widely available, noninvasive, easy to obtain, economic, and rapid to perform. However, there are some major points that have to be considered when interpreting the results by O’Bryant et al. (1) Patients with AD included in the present study were clinically diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA2) criteria for probable AD, and there were no neuropathologically confirmed cases. However, it has been shown in several studies that the agreement between clinical diagnosis and true pathology can vary significantly and may mask a good agreement between a biomarker result and true pathology.3 The implications of using an imperfect reference standard when assessing biomarker performance have to be taken into consideration. (2) The authors proposed a panel of more than 20 serum markers. Including such a high number of parameters can risk overfitting the data set. Overfitting implies poor generalization to correctly classify new data.4 (3) Patients with other subtypes of dementia should be included in the examination in future studies to test the specificity of the described findings in patients with AD. (4) The authors describe the value of adding clinical variables (age, sex, education, APOE status) to their biomarker data. In this context, adding other parameters such as imaging and neuropsychological data to the classifier should be expected to significantly increase diagnostic accuracy. In conclusion, the test performance should be confirmed in further independent validation studies under consideration of the above mentioned points.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

May 1, 2011
Sid E. O’Bryant, PhD
Arch Neurol. 2011;68(5):685-686. doi:10.1001/archneurol.2011.79.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

63 Views
1 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content

brightcove.createExperiences();